Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of “Moderate Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $75.50.

A number of brokerages recently issued reports on PVLA. HC Wainwright upped their price objective on shares of Palvella Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $120.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, October 7th. Canaccord Genuity Group upped their price objective on shares of Palvella Therapeutics from $66.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Truist Financial upped their price target on shares of Palvella Therapeutics from $56.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, October 2nd. Finally, Chardan Capital upped their price target on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 26th.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of PVLA. Federated Hermes Inc. bought a new stake in Palvella Therapeutics during the third quarter valued at about $21,255,000. Millennium Management LLC bought a new stake in Palvella Therapeutics during the first quarter valued at about $7,553,000. Woodline Partners LP bought a new stake in Palvella Therapeutics during the first quarter valued at about $5,435,000. Clio Asset Management LLC bought a new stake in Palvella Therapeutics during the second quarter valued at about $2,063,000. Finally, Geode Capital Management LLC boosted its holdings in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares during the period. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Trading Down 2.3%

Shares of NASDAQ:PVLA opened at $75.06 on Wednesday. The stock has a market capitalization of $830.16 million, a PE ratio of -19.80 and a beta of -0.05. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $83.00. The firm has a fifty day moving average price of $64.72 and a 200 day moving average price of $41.90.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, sell-side analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.